{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:28:33Z","timestamp":1781796513323,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oxaliplatin-based chemotherapy represents a standard of care in the treatment of metastatic colorectal cancer. We report a rare case of fulminant oxaliplatin-induced thrombotic microangiopathy, clinically suggestive of hemolytic\u2013uremic syndrome, occurring in a female patient with a prolonged history of exposure to oxaliplatin for the treatment of metastatic colon cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 73-year-old Caucasian female with a treatment history including several lines of chemotherapy for the management of metastatic colon cancer was reinitiated on chemotherapy with oxaliplatin, fluorouracil, and leucovorin with bevacizumab for disease progression. She presented to the emergency department with malaise, headache, vomiting, and decreased urine output appearing a few hours after chemotherapy administration. Clinical symptoms and laboratory findings were suggestive of thrombotic microangiopathy, with a triad of microangiopathic hemolytic anemia, pronounced thrombocytopenia, and acute renal failure. The predominance of the severe renal failure was evocative of hemolytic\u2013uremic syndrome. The rapid development of the thrombotic microangiopathy was linked to exposure to oxaliplatin. The patient was promptly managed with daily plasma exchange and high-dose corticosteroids, platelet, and red blood cell transfusions in conjunction with intermittent hemodialysis, and she recovered progressively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our case confirms the risk of hemolytic\u2013uremic syndrome as a rare and life-threatening complication of oxaliplatin-based chemotherapy. A dose-dependent, drug-induced toxicity mechanism is suggested. Physicians need to maintain a high level of clinical suspicion to diagnose and treat this acute life-threatening disorder.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03309-7","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:02:36Z","timestamp":1647648156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oxaliplatin-induced thrombotic microangiopathy: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Rhea","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra","family":"Hannun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Temraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Finianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-7780","authenticated-orcid":false,"given":"Rony M.","family":"Zeenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"8","key":"3309_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","volume":"347","author":"JL Moake","year":"2002","unstructured":"Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589\u2013600. https:\/\/doi.org\/10.1056\/NEJMra020528.","journal-title":"N Engl J Med"},{"issue":"4","key":"3309_CR2","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1503\/cmaj.160142","volume":"189","author":"DM Arnold","year":"2017","unstructured":"Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4):E153\u20139. https:\/\/doi.org\/10.1503\/cmaj.160142.","journal-title":"CMAJ"},{"issue":"2","key":"3309_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312\u201322. https:\/\/doi.org\/10.1111\/jth.13571.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"3309_CR4","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","volume":"89","author":"M Furlan","year":"1997","unstructured":"Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, L\u00e4mmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89(9):3097\u2013103.","journal-title":"Blood"},{"issue":"7","key":"3309_CR5","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","volume":"27","author":"T Barbour","year":"2012","unstructured":"Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27(7):2673\u201385. https:\/\/doi.org\/10.1093\/ndt\/gfs279.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3309_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3904\/kjim.2019.388","volume":"35","author":"H Lee","year":"2020","unstructured":"Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25\u201340. https:\/\/doi.org\/10.3904\/kjim.2019.388.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"3309_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616\u20138. https:\/\/doi.org\/10.1182\/blood-2014-11-611335.","journal-title":"Blood"},{"issue":"7","key":"3309_CR8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654\u201366. https:\/\/doi.org\/10.1056\/NEJMra1312353.","journal-title":"N Engl J Med"},{"key":"3309_CR9","unstructured":"George J, Cuker A. Drug-induced thrombotic microangiopathy. In: Post T, editor. UpToDate. Waltham: UpToDate; 2020. www.uptodate.com. Accessed 15 Sept 2020."},{"issue":"11","key":"3309_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-129-11_part_1-199812010-00009","volume":"129","author":"JN George","year":"1998","unstructured":"George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886\u201390. https:\/\/doi.org\/10.7326\/0003-4819-129-11_part_1-199812010-00009.","journal-title":"Ann Intern Med"},{"key":"3309_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6904-6-5","volume":"6","author":"I Dahabreh","year":"2006","unstructured":"Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5. https:\/\/doi.org\/10.1186\/1472-6904-6-5 (Published 2006 Sept 12).","journal-title":"BMC Clin Pharmacol"},{"issue":"3","key":"3309_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ndtplus\/sfp008","volume":"2","author":"NT Phan","year":"2009","unstructured":"Phan NT, Heng AE, Lautrette A, K\u00e9m\u00e9ny JL, Souweine B. Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis. NDT Plus. 2009;2(3):254\u20136. https:\/\/doi.org\/10.1093\/ndtplus\/sfp008.","journal-title":"NDT Plus"},{"issue":"5","key":"3309_CR13","doi-asserted-by":"publisher","first-page":"31e-3e","DOI":"10.1700\/989.10735","volume":"97","author":"P Racca","year":"2011","unstructured":"Racca P, Spadi R, Fora G, et al. Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report. Tumori. 2011;97(5):31e-3e. https:\/\/doi.org\/10.1700\/989.10735.","journal-title":"Tumori"},{"issue":"4","key":"3309_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2. 2018. J Natl Compr Cancer Netw. 2018;16(4):359\u201369. https:\/\/doi.org\/10.6004\/jnccn.2018.0021.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"3309_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4103\/0973-1482.154056","volume":"12","author":"GU Erdem","year":"2016","unstructured":"Erdem GU, Dogan M, Demirci NS, Zengin N. Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 2016;12(2):509\u201314. https:\/\/doi.org\/10.4103\/0973-1482.154056.","journal-title":"J Cancer Res Ther"},{"issue":"31","key":"3309_CR16","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1200\/JCO.2012.42.5082","volume":"30","author":"J Niu","year":"2012","unstructured":"Niu J, Mims MP. Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. J Clin Oncol. 2012;30(31):e312\u20134. https:\/\/doi.org\/10.1200\/JCO.2012.42.5082.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3309_CR17","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1200\/JCO.2012.48.3248","volume":"31","author":"A Lucchesi","year":"2013","unstructured":"Lucchesi A, Carloni S, Cangini D, Frassineti GL, Casadei GA. Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report and results from a cytoflourimetric assay of platelet fibrinogen receptor. J Clin Oncol. 2013;31(16):2061\u20132. https:\/\/doi.org\/10.1200\/JCO.2012.48.3248.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3309_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.clcc.2013.09.002","volume":"12","author":"Z Baretta","year":"2013","unstructured":"Baretta Z, Falci C, Piva E, Conte P. Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report. Clin Colorectal Cancer. 2013;12(4):294\u20136. https:\/\/doi.org\/10.1016\/j.clcc.2013.09.002.","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"3309_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171\u2013354. https:\/\/doi.org\/10.1002\/jca.21705.","journal-title":"J Clin Apher"},{"issue":"4","key":"3309_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/1078155218774895","volume":"25","author":"A Vakiti","year":"2019","unstructured":"Vakiti A, Singh D, Pilla R, Alhaj-Moustafa M, Fitzpatrick KW. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. J Oncol Pharm Pract. 2019;25(4):1011\u20135. https:\/\/doi.org\/10.1177\/1078155218774895.","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"3309_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336. https:\/\/doi.org\/10.1056\/NEJMoa0707330.","journal-title":"N Engl J Med"},{"issue":"4","key":"3309_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1182\/blood.V96.4.1223","volume":"96","author":"JN George","year":"2000","unstructured":"George JN. How I treat patients with thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome. Blood. 2000;96(4):1223\u20139.","journal-title":"Blood"},{"issue":"1","key":"3309_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/asheducation-2017.1.632","volume":"2017","author":"JL Winters","year":"2017","unstructured":"Winters JL. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematol Am Soc Hematol Educ Progr. 2017;2017(1):632\u20138. https:\/\/doi.org\/10.1182\/asheducation-2017.1.632.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"1","key":"3309_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125. https:\/\/doi.org\/10.1186\/s12882-019-1314-1 (Published 2019 Apr 10).","journal-title":"BMC Nephrol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03309-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03309-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03309-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:02:58Z","timestamp":1647648178000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03309-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03309-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}